<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05624944</url>
  </required_header>
  <id_info>
    <org_study_id>TS142-303</org_study_id>
    <nct_id>NCT05624944</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment</brief_title>
  <official_title>An Open-label Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label pharmacokinetic study of TS-142 in patients with hepatic impairment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2022</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Plasma concentration of unchanged form and its metabolite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Maximum plasma concentration of unchanged form and its metabolite (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Time to maximum plasma concentration of unchanged form and its metabolite (tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Area under the plasma concentration-time curve extrapolated to infinity of unchanged form and its metabolite (AUCinf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration of unchanged form and its metabolite (AUC0-last)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Terminal elimination rate constant of unchanged form and its metabolite (Î»z)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Elimination half-life of unchanged form and its metabolite (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Apparent volume of distribution based on the terminal phase of unchanged form (Vz/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Apparent total body clearance of unchanged form (CL/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Plasma unbound fraction of unchanged form and its metabolite (fu)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Maximum plasma concentration adjusted by unbound fraction of unchanged form (Cmax(unbound))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Area under the plasma concentration-time curve extrapolated to infinity adjusted by unbound fraction of unchanged form (AUC(unbound))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Predose and up to 48 hours postdose</time_frame>
    <description>Apparent total body clearance adjusted by unbound fraction of unchanged form (CL(unbound)/F)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From administration of investigational product through 10 days after administration of investigational product</time_frame>
    <description>&quot;Adverse event&quot; refers to any unfavorable or unintended disease or symptom thereof (including abnormal laboratory tests values) occurring in a subject who has been administered an investigational product, whether or not there is a causal relationship with the investigational product.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Patients With Mild or Moderate Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mild hepatic impairment will receive a single-dose of 5 mg of TS-142</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with moderate hepatic impairment will receive a single-dose of 5 mg of TS-142</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with normal hepatic function will receive a single-dose of 5 mg of TS-142</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-142 5 mg</intervention_name>
    <description>Single-dose of 5 mg of TS-142</description>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_label>Normal hepatic function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        &lt;Inclusion criteria for patients with hepatic impairment&gt;&#xD;
&#xD;
          1. Japanese male and female who are aged 18 to 75 years at the time of informed consent&#xD;
&#xD;
          2. Patients with cirrhosis&#xD;
&#xD;
          3. Patients classified as Child-Pugh classification A (mild) or B (moderate) by the&#xD;
             principal investigator or sub-investigator at the screening test Other protocol&#xD;
             defined inclusion criteria could apply.&#xD;
&#xD;
        &lt;Inclusion criteria for subject with normal hepatic function&gt;&#xD;
&#xD;
          1. Japanese male and female who are aged 18 to 75 years at the time of informed consent&#xD;
&#xD;
          2. Body Mass Index (BMI) between 18.5 and 35.0 at the screening test Other protocol&#xD;
             defined inclusion criteria could apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        &lt;Exclusion criteria for patients with hepatic impairment&gt;&#xD;
&#xD;
          1. Patients who have a history of liver resection or liver transplant&#xD;
&#xD;
          2. Patients with hepatic encephalopathy of grade II or higher&#xD;
&#xD;
          3. Patients with epidermal growth factor receptor (eGFR) less than 45 mL/min/1.73 m2 at&#xD;
             the screening test Other protocol defined exclusion criteria could apply.&#xD;
&#xD;
        &lt;Exclusion criteria for subjects with normal hepatic function&gt;&#xD;
&#xD;
          1. Subjects who are judged to have any disease by the principal investigator or&#xD;
             sub-investigator&#xD;
&#xD;
          2. Subjects with eGFR less than 60 mL/min/1.73 m2 at the screening test Other protocol&#xD;
             defined exclusion criteria could apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisho Director</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taisho Pharmaceutical Co., Ltd.</last_name>
    <phone>81-3-3985-1118</phone>
    <email>clinical-trials_CTG@taisho.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taisho Pharmaceutical Co., Ltd selected site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taisho Director</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>November 11, 2022</study_first_submitted>
  <study_first_submitted_qc>November 20, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>December 27, 2022</last_update_submitted>
  <last_update_submitted_qc>December 27, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

